Clinical Trial Update: A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II clinical trial evaluating DYP688 in patients with metastatic uveal melanoma and other GNAQ/11-mutant melanomas; the study is currently active but n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Uveal Melanoma

Drugs mentioned

• DYP688

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Uveal Melanoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING